Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
A new study has calculated the average cost per case of TB in the EU. The findings suggest the economic burden of TB far outweighs the costs of investing in more effective vaccines.
The research, published online today (16 August 2013), in the European Respiratory Journal, is the first study to estimate the costs of the disease in recent years.
Researchers used a systematic review of literature and institutional websites for the 27 EU member states to summarise economic data on the treatment cost of TB cases in 2011.
The researchers separated the countries into two groups based on their gross domestic product (GDP) per person. The findings revealed the costs as follows:
For the old EU-15 countries, plus Cyprus, Malta and Slovenia, on average the costs per case were:
For the remaining new EU states, the costs amounted to:
The authors calculated that of the total treatment cost of drug-susceptible, MDR-TB and XDR-TB cases in 2011 was €536,890,315.
The researchers also calculated the disability-adjusted life years (DALYs) caused by TB. DALYs are a measure of disease burden, looking at the number of years lost due to ill-health, disability or early death. The total number of years lost amounted to 103,104 in 2011. When stated in monetary terms, this amounted to €5,361,408,000.
The findings come ahead of the launch of the European Lung White Book, a comprehensive publication that will provide burden and cost data for a range of respiratory diseases and risk factors. The launch will take place at this year's European Respiratory Society's Annual Congress in Barcelona next month (7 September 2013).
Lead author, Roland Diel, professor for Health Economics at the University Hospital Schleswig?"Holstein in Kiel, Germany, , said: "This is the first time that a comprehensive cost-per-case has been estimated for TB. Without better vaccines, it is unlikely that tuberculosis (TB) will ever be eliminated. An investment of about 560 million is considered necessary to develop a new, effective vaccine in the EU.
"The findings of our study suggest that this investment is essential as the costs of the current economic burden far outweigh the cost of investing in new treatments."
Francesco Blasi, President of the European Respiratory Society, said: "The figures in this study have shown that the burden of TB on both the economy and on society in Europe is huge, particularly with the increasing problem of drug-resistant strains. The widely used BCG vaccine was introduced in 1921; it is out of date and has unpredictable success in preventing TB. It is time to invest more of our resources in preventing this debilitating condition.
"It is critical that healthcare professionals and policymakers take note of this new data to understand the impact and burden of diseases. That is why we have produced the White Book, which includes the latest data on over 20 different respiratory diseases in Europe."
Title: Costs of tuberculosis disease in the EU: a systematic analysis and cost calculation Authors: Diel R, Vandeputte J, de Vries, G, Stillo J, Wanlin, M, Nienhaus, A DOI: 10.1183/09031936.00079413
 The study was carried out before Croatia joined the EU on 1 July 2013.
The European Lung Foundation
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Tuberculosis category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
The European Lung Foundation. "New study puts a price on drug-resistant TB cases in EU." Medical News Today. MediLexicon, Intl., 16 Aug. 2013. Web.
19 Dec. 2013. <http://www.medicalnewstoday.com/releases/264896>
The European Lung Foundation. (2013, August 16). "New study puts a price on drug-resistant TB cases in EU." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact the our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2013 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.